

Treatment with Humanized Selective CD19CAR-T Cells Shows Efficacy in Highly Treated B-ALL Patients Who Have Relapsed after Receiving Murine-Based CD19CAR-T Therapies

Yu Zhao, Zhongfeng Liu, Xuan Wang, et al.

Clin Cancer Res Published OnlineFirst July 12, 2019.

Updated version	Access the most recent version of this article at: doi: 10.1158/1078-0432.CCR-19-0916
Supplementary Material	Access the most recent supplemental material at: http://clincancerres.aacrjournals.org/content/suppl/2019/07/12/1078-0432.CCR-19-0916.DC1

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/early/2019/08/07/1078-0432.CCR-19-0916 . Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.